Diabetes and Neuroaxonal Damage in Parkinson's Disease

PRoBaND Clinical Consortium

Research output: Contribution to journalArticle (Academic Journal)peer-review

5 Citations (Scopus)
26 Downloads (Pure)
Original languageEnglish
Pages (from-to)1568-1569
Number of pages2
JournalMovement Disorders
Volume37
Issue number7
DOIs
Publication statusPublished - Jul 2022

Bibliographical note

Funding Information:
H.Z. is a Wallenberg scholar supported by grants from the Swedish Research Council (2018‐02532); the European Research Council (681712 and 101053962); the Swedish State Support for Clinical Research (ALFGBG‐71320); the Alzheimer Drug Discovery Foundation, USA (201809‐2016862); the AD Strategic Fund and the Alzheimer's Association (ADSF‐21‐831376‐C, ADSF‐21‐831381‐C, and ADSF‐21‐831377‐C); the Olav Thon Foundation; the Erling‐Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2019‐0228); the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska–Curie grant agreement number 860197 (MIRIADE); the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021‐00694); and the UK Dementia Research Institute at UCL (UKDRI‐1003). D.G.G. has received grant funding from the Neurosciences Foundation, Michael's Movers, and Parkinson's UK. Funding agencies:

Funding Information:
Cohort studies: Tracking Parkinson's is primarily funded and supported by Parkinson's UK. It is also supported by the National Institute for Health Research Dementias and Neurodegenerative Diseases Research Network. This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and Cambridge BRC. The UCL Movement Disorders Centre is supported by the Edmond J. Safra Philanthropic Foundation. Biomarker analysis: Work on the biomarkers of progression in Parkinson's and related disorders is supported by Parkinson's UK and the PSP Association. This research was funded in whole or in part by Aligning Science Across Parkinson's (grant no.: ASAP-000478) through The Michael J. Fox Foundation for Parkinson's Research. For open access, the author has applied a CC BY public copyright license to all author-accepted manuscripts resulting from this submission.

Funding Information:
H.R.M. is employed by UCL. In the past 24 months he reports paid consultancy from Biogen, UCB, AbbVie, Denali, Biohaven, and Lundbeck; lecture fees/honoraria from Biogen, UCB, C4X Discovery, GE‐Healthcare, Wellcome Trust, and Movement Disorders Society; and research grants from ASAP, Parkinson's UK, Cure Parkinson's Trust, PSP Association, CBD Solutions, Drake Foundation, and Medical Research Council. Dr. Morris is a co‐applicant on a patent application related to C9ORF72—Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140).

Funding Information:
T.F. has received grants from the National Institute of Health Research, The Michael J. Fox Foundation, John Black Charitable Foundation, Cure Parkinson's Trust, Innovate UK, Van Andel Research Institute, and Defeat MSA. He has served on advisory boards for Voyager Therapeutics, Handl Therapeutics, Living Cell Technologies, Bial, and Profile Pharma. He has received honoraria for talks sponsored by Bial, Profile Pharma, and Boston Scientific.

Keywords

  • Diabetes Mellitus
  • Humans
  • Parkinson Disease/complications

Cite this